BMI View: Despite the French government partially abandoning fiscal deficit targets in its 2015 budget,
cost-containment measures will continue to weigh on the pharmaceuticals and healthcare sector for the
foreseeable future. The government's strategy of emphasising preventive ..."
BMI View: A number of biologics will lose patent protection between now and 2015, which means that
France's biosimilar substitution legislation will pave the way to cost savings in the healthcare system.
However, we question the strength of this legislation, as develo ..."
BMI View: While regional growth is showing signs of improvement, we expect France's economic activity
will lag behind its regional peers, restrained by persistently high levels of unemployment and ongoing
competitiveness issues. We forecast zero real GDP growth in 201 ..."
BMI View: We expect pressures on the French government to mount over the coming quarters encouraging it to engage in more concerted fiscal consolidation, particularly as lower growth begins to translate into lower government revenues. We believe that the pharmaceuticals and healt ..."
BMI View: In line with our view that France will miss its fiscal deficit target of 3.0% of GDP in 2013 (and
we maintain our forecast of 3.5%) we expect the government to engage in more concerted fiscal
consolidation over the coming quarters - with a heavy foc ..."
France's high public debt-to-GDP ratio will necessitate more aggressive fiscal tightening by the state. This includestargeting the pharmaceuticals and healthcare sector, whichcurrentlyreceivesa large proportion of public funds.
Headline Expenditure Projections ..."
BMI View: France's high public debt-to-GDP ratio will necessitate more aggressive fiscal tightening by
the state. This includes targeting the pharmaceuticals and healthcare sector, which currently receives a
large proportion of public funds.
Headline Expenditure Projections